Novartis: Decentralized trials could expand enterprise around the world

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/RomoloTavani)
(Image: Getty/RomoloTavani)
Novartis hopes to eventually recruit ‘a significant portion’ of patients into a decentralized clinical trial model that has the potential to increase the company’s reach globally, says exec.

Last week Novartis and Science 37 announced​ an expanded alliance through which the companies will launch up to 10 “decentralized” clinical trials across the US.

Decentralized trials shift some or all aspects of a clinical trial from a central site, such as a hospital, to the participant’s home or physician’s office.

“By bringing the trial to the patient, Novartis aims to decrease the burden of clinical trial participation on patients and trial centers,”​ Jake LaPorte, global head of digital development at Novartis told Outsourcing-Pharma.com.

The more flexible approach also could benefit underrepresented populations.

LaPorte said: “This approach also has the potential to increase the reach of our leading drug development and clinical trials enterprise into under-represented and underserved populations around the world, improving the caliber and quantity of data available to aid in drug discovery and development.”

Currently, Novartis is in the process of selecting specific indication and trials where it will deploy the decentralized approach, which leverages Science 37’s technology to enable patient participation using mobile devices and telemedicine services.

LaPorte said the characteristics of the target patient population, including size, will be defined after these decisions have been made.

The studies will use both decentralized and traditional models, “with the aspiration of attaining increasing degrees of decentralization towards a mostly ‘site-less’ model overtime,”​ he added.

Our aspiration, overtime, is to recruit a significant portion of patients into this decentralized model when deployed on a clinical trial.”

Related news

Show more

Related products

show more

Next generation ePRO from SQN Health

Next generation ePRO from SQN Health

In an era of rapid technology growth, healthcare requires low cost solutions for real-time data collection. We have come a long way from paper to EDC and...

baxter_bloomington_facility_larger

Sterile Injectables Contract Manufacturing

Baxter BioPharma Solutions | 02-Apr-2018 | Product Brochure

Baxter BioPharma Solutions' award-winning facility in Bloomington, Indiana, USA, is a leader in sterile contract manufacturing of injectable products.

lyo_development

Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

Related suppliers

Follow us

Products

View more